| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
37,343 |
31,545 |
$5.46M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
33,005 |
29,379 |
$4.85M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
31,863 |
27,739 |
$4.60M |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
5,248 |
1,635 |
$2.61M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
24,550 |
17,895 |
$2.09M |
| A0429 |
Ambulance service, basic life support, emergency transport (bls-emergency) |
12,910 |
9,909 |
$1.59M |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
4,185 |
3,461 |
$1.53M |
| A0427 |
Ambulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) |
8,522 |
7,063 |
$1.26M |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
14,251 |
12,376 |
$978K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
14,646 |
12,281 |
$873K |
| A0425 |
Ground mileage, per statute mile |
31,804 |
21,293 |
$662K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
450 |
401 |
$651K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
3,943 |
1,560 |
$527K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
7,164 |
6,012 |
$422K |
| 99215 |
Prolong outpt/office vis |
4,615 |
4,079 |
$419K |
| 71046 |
Radiologic examination, chest; 2 views |
4,476 |
3,799 |
$405K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
5,499 |
5,009 |
$378K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,076 |
880 |
$325K |
| A0428 |
Ambulance service, basic life support, non-emergency transport, (bls) |
8,893 |
4,905 |
$313K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
9,547 |
7,672 |
$302K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
8,716 |
7,302 |
$295K |
| 80050 |
General health panel |
1,769 |
1,502 |
$275K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
70,921 |
54,787 |
$265K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
2,221 |
1,843 |
$237K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
19,386 |
15,911 |
$224K |
| 93296 |
|
1,162 |
960 |
$211K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,489 |
1,327 |
$206K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
2,748 |
1,711 |
$204K |
| 80053 |
Comprehensive metabolic panel |
35,002 |
26,766 |
$189K |
| 36415 |
Collection of venous blood by venipuncture |
89,889 |
69,209 |
$176K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,319 |
1,129 |
$151K |
| 71045 |
Radiologic examination, chest; single view |
872 |
749 |
$141K |
| 36591 |
|
2,530 |
1,064 |
$133K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,929 |
2,420 |
$130K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
941 |
779 |
$123K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,172 |
1,823 |
$107K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,176 |
1,026 |
$93K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
920 |
255 |
$79K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
20,640 |
16,321 |
$72K |
| 70450 |
Computed tomography, head or brain; without contrast material |
878 |
757 |
$68K |
| 84443 |
Thyroid stimulating hormone (TSH) |
6,886 |
6,060 |
$66K |
| 84484 |
|
7,856 |
6,225 |
$65K |
| 87634 |
|
1,200 |
1,065 |
$62K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,152 |
1,947 |
$55K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
598 |
494 |
$54K |
| 87481 |
|
1,039 |
883 |
$52K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
868 |
775 |
$51K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
297 |
224 |
$49K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
10,527 |
7,734 |
$48K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
764 |
665 |
$47K |
| 80061 |
Lipid panel |
5,290 |
4,850 |
$47K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,865 |
2,249 |
$43K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
8,349 |
6,697 |
$41K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
2,557 |
2,343 |
$40K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,468 |
1,288 |
$37K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,448 |
1,274 |
$37K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
2,044 |
1,817 |
$35K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,398 |
1,172 |
$34K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,138 |
947 |
$34K |
| 87512 |
|
1,041 |
884 |
$33K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
4,696 |
4,201 |
$28K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
19 |
12 |
$27K |
| 84145 |
|
1,723 |
1,351 |
$27K |
| 83605 |
|
3,741 |
2,958 |
$24K |
| 81001 |
|
13,312 |
11,047 |
$24K |
| 83690 |
|
7,131 |
5,920 |
$23K |
| Q3014 |
Telehealth originating site facility fee |
308 |
271 |
$23K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
312 |
254 |
$21K |
| 86780 |
|
2,152 |
1,909 |
$21K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
506 |
455 |
$19K |
| 82728 |
|
3,171 |
2,498 |
$19K |
| 85027 |
|
3,825 |
3,476 |
$19K |
| 81025 |
|
3,713 |
3,125 |
$19K |
| 90677 |
|
167 |
111 |
$18K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
767 |
429 |
$17K |
| 71250 |
|
95 |
68 |
$15K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
179 |
162 |
$14K |
| 92567 |
|
441 |
382 |
$14K |
| 83735 |
|
4,413 |
2,390 |
$14K |
| 86803 |
|
1,336 |
1,205 |
$14K |
| 82607 |
|
1,761 |
1,604 |
$13K |
| 88312 |
|
814 |
692 |
$13K |
| 83550 |
|
3,116 |
2,476 |
$12K |
| 36416 |
|
2,086 |
1,593 |
$12K |
| 96367 |
|
563 |
243 |
$10K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
628 |
557 |
$10K |
| 84439 |
|
1,713 |
1,285 |
$10K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
42 |
36 |
$10K |
| 86762 |
|
946 |
824 |
$10K |
| 82248 |
|
3,103 |
2,571 |
$9K |
| 83540 |
|
3,135 |
2,494 |
$9K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
12 |
12 |
$8K |
| 83970 |
|
566 |
503 |
$8K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
304 |
266 |
$7K |
| 83037 |
|
1,532 |
1,265 |
$7K |
| 84100 |
|
3,059 |
1,360 |
$7K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
402 |
349 |
$7K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
545 |
464 |
$6K |
| 92587 |
|
198 |
170 |
$6K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
141 |
139 |
$6K |
| 87340 |
|
1,074 |
932 |
$6K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
16 |
15 |
$5K |
| 99205 |
Prolong outpt/office vis |
60 |
52 |
$5K |
| 80076 |
|
1,858 |
1,524 |
$5K |
| 90670 |
|
17 |
16 |
$5K |
| 80069 |
|
1,277 |
1,107 |
$5K |
| P9603 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled |
5,545 |
3,660 |
$5K |
| 91322 |
|
122 |
101 |
$5K |
| 86850 |
|
1,023 |
883 |
$4K |
| 81003 |
|
3,916 |
3,318 |
$4K |
| 82962 |
|
2,147 |
1,746 |
$4K |
| 11045 |
|
28 |
15 |
$4K |
| 73610 |
|
198 |
186 |
$4K |
| 85380 |
|
600 |
514 |
$4K |
| 90791 |
Psychiatric diagnostic evaluation |
63 |
50 |
$3K |
| 73130 |
|
172 |
155 |
$3K |
| J7050 |
Infusion, normal saline solution, 250 cc |
126 |
19 |
$3K |
| 73630 |
|
145 |
138 |
$3K |
| A0426 |
Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) |
14 |
14 |
$3K |
| 12001 |
|
12 |
12 |
$2K |
| 83525 |
|
235 |
219 |
$2K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
124 |
39 |
$2K |
| 84481 |
|
136 |
127 |
$2K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
161 |
67 |
$2K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
267 |
93 |
$2K |
| 84702 |
|
217 |
163 |
$2K |
| 84482 |
|
125 |
117 |
$2K |
| 82570 |
|
382 |
358 |
$2K |
| 86900 |
|
832 |
713 |
$2K |
| 86376 |
|
128 |
114 |
$2K |
| J1756 |
Injection, iron sucrose, 1 mg |
68 |
17 |
$2K |
| 86901 |
|
832 |
713 |
$2K |
| 88142 |
|
127 |
115 |
$2K |
| 87653 |
|
69 |
58 |
$1K |
| 74018 |
|
22 |
18 |
$1K |
| 90480 |
|
121 |
100 |
$1K |
| 36592 |
|
242 |
140 |
$1K |
| 0124A |
|
389 |
240 |
$1K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
221 |
62 |
$1K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
17 |
14 |
$1K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
12 |
12 |
$1K |
| 84550 |
|
348 |
308 |
$1K |
| 96116 |
|
61 |
49 |
$1K |
| 87522 |
Neg quan hep c or qual rna |
30 |
27 |
$1K |
| 83880 |
|
76 |
66 |
$1K |
| 82043 |
|
323 |
305 |
$1K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
33 |
12 |
$970.55 |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
41 |
33 |
$964.99 |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
1,112 |
587 |
$781.29 |
| 73110 |
|
25 |
25 |
$738.73 |
| 59025 |
Fetal non-stress test |
171 |
102 |
$703.66 |
| 86480 |
|
30 |
24 |
$681.78 |
| 92579 |
|
34 |
26 |
$670.85 |
| 87070 |
|
104 |
94 |
$640.44 |
| 87077 |
|
251 |
215 |
$595.61 |
| 90686 |
|
1,684 |
1,323 |
$570.58 |
| 87186 |
|
234 |
200 |
$549.30 |
| 84155 |
|
245 |
230 |
$522.90 |
| 88300 |
|
12 |
12 |
$458.64 |
| 83516 |
|
32 |
16 |
$446.69 |
| 80074 |
|
13 |
13 |
$428.67 |
| 96118 |
|
17 |
12 |
$418.60 |
| 85610 |
|
186 |
152 |
$357.68 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
12 |
12 |
$322.44 |
| G0008 |
Administration of influenza virus vaccine |
1,936 |
1,475 |
$313.95 |
| 87210 |
|
128 |
120 |
$310.20 |
| 90834 |
Psychotherapy, 45 minutes with patient |
15 |
12 |
$265.23 |
| 83090 |
|
34 |
25 |
$210.76 |
| 87081 |
|
53 |
44 |
$201.86 |
| 80055 |
|
17 |
16 |
$184.25 |
| 84146 |
|
13 |
13 |
$180.61 |
| 73562 |
|
35 |
28 |
$175.09 |
| 97803 |
|
41 |
40 |
$142.76 |
| 85652 |
|
96 |
86 |
$136.33 |
| 85014 |
|
69 |
63 |
$129.54 |
| 85018 |
|
69 |
63 |
$129.53 |
| 85730 |
|
40 |
36 |
$122.43 |
| 86256 |
|
13 |
12 |
$117.00 |
| 0002A |
|
82 |
71 |
$115.08 |
| 82950 |
|
30 |
26 |
$100.25 |
| 87040 |
|
48 |
44 |
$95.78 |
| 82784 |
|
13 |
12 |
$92.25 |
| 0004A |
|
152 |
99 |
$86.16 |
| 86140 |
|
19 |
16 |
$81.07 |
| 87015 |
|
18 |
14 |
$66.80 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
12 |
12 |
$57.33 |
| 82746 |
|
52 |
48 |
$45.28 |
| 90662 |
|
12 |
12 |
$44.72 |
| 87205 |
|
44 |
40 |
$35.93 |
| 0054A |
|
52 |
37 |
$35.67 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
919 |
730 |
$9.87 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
5,268 |
4,379 |
$4.92 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
5,369 |
4,309 |
$1.67 |
| 0001A |
|
40 |
37 |
$0.60 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
1,311 |
1,027 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
566 |
458 |
$0.00 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
5,878 |
1,475 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
1,871 |
1,461 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
698 |
584 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
1,905 |
1,500 |
$0.00 |
| 99406 |
|
480 |
397 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
15 |
14 |
$0.00 |
| J2780 |
Injection, ranitidine hydrochloride, 25 mg |
24 |
15 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,377 |
575 |
$0.00 |
| G0471 |
Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) |
2,190 |
1,129 |
$0.00 |
| G0009 |
Administration of pneumococcal vaccine |
150 |
109 |
$0.00 |
| 96376 |
|
123 |
97 |
$0.00 |
| Q2036 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) |
311 |
276 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
152 |
125 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
44 |
43 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
139 |
123 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
336 |
265 |
$0.00 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
611 |
493 |
$0.00 |
| 90658 |
|
71 |
57 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
97 |
83 |
$0.00 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
124 |
53 |
$0.00 |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
27 |
25 |
$0.00 |
| 90715 |
|
78 |
69 |
$0.00 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
33 |
30 |
$0.00 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
111 |
100 |
$0.00 |
| 99188 |
|
12 |
12 |
$0.00 |